ANTERIS TECHNOLOGIES GLOBAL CORP. - Announcements

8.04%

$6.05

Market Cap $92.87M

Healthcare Medical Devices

Anteris Technologies Global Corp. is a structural heart company, which is engaged in... Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

AVR	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/14	149.83KB	Share
AVR	Admedus's CardioCel Cleared for Sale in the US	PRICE SENSITIVE	10/02/14	279.96KB	Share
AVR	Admedus Herpes Interim Phase I Results	PRICE SENSITIVE	03/02/14	277.59KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/14	412.6KB	Share
AVR	Change in substantial holding		13/01/14	562.85KB	Share
AVR	Admedus completes acquisition of manufacturing facility		03/01/14	180.84KB	Share
AVR	Admedus End of Year Update	PRICE SENSITIVE	24/12/13	278.97KB	Share
AVR	Change of Director's Interest Notice - Correction		18/12/13	316.82KB	Share
AVR	Change of Director's Interest Notices		17/12/13	332.46KB	Share
AVR	Appendix 3B & Notice under Section 708A		17/12/13	702.92KB	Share
AVR	Admedus Acquires Manufacturing Facility	PRICE SENSITIVE	12/12/13	223.93KB	Share
AVR	Change of Company Name		21/11/13	189.26KB	Share
AVR	Results of Meeting		20/11/13	106.5KB	Share
AVR	Presentation to Shareholders		20/11/13	4.72MB	Share
AVR	Chairman's Address to Shareholders		20/11/13	111.53KB	Share
AVR	Allied makes first sale of CardioCel into Europe	PRICE SENSITIVE	08/11/13	184.28KB	Share
AVR	Appendix 3B - Options & Notice under Section 708A		04/11/13	805.7KB	Share
AVR	Change in substantial holding		04/11/13	567.9KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/13	467.99KB	Share
AVR	Allied awarded Industry's Emerging Company of the Year		31/10/13	287.98KB	Share
AVR	Response to ASX price query	PRICE SENSITIVE	25/10/13	326.34KB	Share
AVR	Change in substantial holding		25/10/13	766.15KB	Share
AVR	Top 20 securityholders		25/10/13	258.37KB	Share
AVR	Change of Director's Interest Notices		25/10/13	327.81KB	Share
AVR	Appendix 3B - Rights Issue		25/10/13	721.4KB	Share
AVR	Allied completes oversubscribed $10.4 million Rights Issue		23/10/13	202.78KB	Share
AVR	Waiver to Listing Rule 10.13.5		22/10/13	269.14KB	Share
AVR	Full Annual Report to shareholders		21/10/13	4.96MB	Share
AVR	Proxy Form		21/10/13	332.75KB	Share
AVR	Notice of Annual General Meeting		21/10/13	702.98KB	Share
AVR	Allied Herpes Phase I Trial progress update	PRICE SENSITIVE	17/10/13	269.31KB	Share
AVR	Appendix 3B - Exercise of Options		08/10/13	719.61KB	Share
AVR	8 Surgeons get approval to use CardioCel in adult patients	PRICE SENSITIVE	08/10/13	199.58KB	Share
AVR	Dispatch of Offer Document		03/10/13	197.56KB	Share
AVR	Change of Director's Interest Notice		27/09/13	224.68KB	Share
AVR	Appendix 3B - Exercise of Options		27/09/13	719.27KB	Share
AVR	5 year extension data for Allied's CardioCel	PRICE SENSITIVE	25/09/13	288.61KB	Share
AVR	Letter to Ineligible Shareholders		23/09/13	115.54KB	Share
AVR	Letter to Eligible Shareholders		23/09/13	117.67KB	Share
AVR	Letter to Optionholders		23/09/13	123.74KB	Share
AVR	Appendix 3B - Rights Issue		23/09/13	569.04KB	Share
AVR	Non-Renounceable Issue Offer Document	PRICE SENSITIVE	23/09/13	501.27KB	Share
AVR	Allied announces fully underwritten Rights Issue	PRICE SENSITIVE	23/09/13	312.62KB	Share
AVR	Notice under Section 708AA		23/09/13	191.41KB	Share
AVR	Exercise of Options		18/09/13	719.18KB	Share
AVR	Appendix 3B - Exercise of Options		11/09/13	733.43KB	Share
AVR	Investor Presentation		11/09/13	1.2MB	Share
AVR	Appendix 3B - Exercise of Options		06/09/13	719.27KB	Share
AVR	Appendix 3B - Exercise of Options		04/09/13	718.91KB	Share
AVR	Allied Herpes Vaccine Phase I Trial Update	PRICE SENSITIVE	03/09/13	194.72KB	Share
AVR	Annual Report to shareholders and Appendix 4E	PRICE SENSITIVE	30/08/13	1.94MB	Share
AVR	Appendix 3B - Exercise of Options		30/08/13	630.19KB	Share
AVR	Cancellation of Unlisted Options		27/08/13	174.63KB	Share
AVR	Appendix 3B - Exercise of Options		27/08/13	719.44KB	Share
AVR	Allied granted CE Mark for CardioCel	PRICE SENSITIVE	26/08/13	201.44KB	Share
AVR	Response to ASX price query	PRICE SENSITIVE	20/08/13	332.66KB	Share
AVR	Change in substantial holding		30/07/13	88.44KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/13	469.16KB	Share
AVR	Shareholder Newsletter - June 2013		11/07/13	147.59KB	Share
AVR	Replacement - Appendix 3B		08/07/13	730.26KB	Share
AVR	Section 708A Notice		08/07/13	135.26KB	Share
AVR	Appendix 3B		08/07/13	730.55KB	Share
AVR	Adult Surgeon approved to use Allied's CardioCel		08/07/13	198.42KB	Share
AVR	Allied increases stake in Ian Frazer's Coridon vaccines	PRICE SENSITIVE	01/07/13	196.14KB	Share
AVR	Appendix 3B - ESOP		20/06/13	730.25KB	Share
AVR	Ceasing to be a substantial holder		20/06/13	459.25KB	Share
AVR	Allied's Herpes Vaccine Progresses to Phase 1 Clinical Trial	PRICE SENSITIVE	19/06/13	181.05KB	Share
AVR	Change in substantial holding		05/06/13	852.22KB	Share
AVR	Allied's CardioCel receives $1.9M grant	PRICE SENSITIVE	03/06/13	225.42KB	Share
AVR	Allied's CardioCel in Spotlight at International Conferences	PRICE SENSITIVE	06/05/13	202.44KB	Share
AVR	Appendix 3B - Options		02/05/13	729.96KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/13	470.69KB	Share
AVR	Allied Announces Additional Early Access for CardioCel	PRICE SENSITIVE	08/04/13	278.62KB	Share
AVR	Shareholder Newsletter - March 2013		27/03/13	860.1KB	Share
AVR	Clinical Trial Extension Study Update - No Calcification	PRICE SENSITIVE	06/03/13	202.33KB	Share
AVR	Half Yearly Report	PRICE SENSITIVE	22/02/13	134.2KB	Share
AVR	Response to ASX query	PRICE SENSITIVE	19/02/13	352.13KB	Share
AVR	Replacement form - Change in substantial holding		15/02/13	128.15KB	Share
AVR	Allied announces ISO 13485 certification for CardioCel	PRICE SENSITIVE	13/02/13	202.01KB	Share
AVR +AVX	Ceasing to be a substantial holder		11/02/13	140.96KB	Share
AVR	Amended form - change in substantial holding		07/02/13	846.12KB	Share
AVR	Allied's CardioCel superior for seeding stem cells	PRICE SENSITIVE	06/02/13	704.27KB	Share
AVR	Change in substantial holding		04/02/13	1.25MB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/13	449.71KB	Share
AVR	Change of Director's Interest Notices		29/01/13	309.94KB	Share
AVR	Top 20 securityholders		29/01/13	229.74KB	Share
AVR	Appendix 3B - Share Purchase Plan		29/01/13	752.77KB	Share
AVR	Allied closes SPP, bringing total capital raised to $4.6M		23/01/13	266.56KB	Share
AVR	Allied's hernia and pelvic floor results	PRICE SENSITIVE	10/01/13	280.04KB	Share
AVR	Top 20 securityholders		21/12/12	228.99KB	Share
AVR	Appendix 3B and Section 708A(5)(e) Notice		21/12/12	752.61KB	Share
AVR	Allied announces successful grant for Coridon's HPV vaccine	PRICE SENSITIVE	20/12/12	266.22KB	Share
AVR	Allied Announces Placement and Share Purchase Plan	PRICE SENSITIVE	17/12/12	207.44KB	Share
AVR	Trading Halt	PRICE SENSITIVE	13/12/12	75.83KB	Share
AVR	Re-issue correction to Appendix 3B		10/12/12	562.45KB	Share
AVR	Change of Director's Interest Notice		07/12/12	291.5KB	Share
AVR	Appendix 3B		07/12/12	402.47KB	Share
AVR	Change in substantial holding		07/12/12	84.09KB	Share
AVR	Allied's CardioCel shows regeneration in heart valve study	PRICE SENSITIVE	28/11/12	221.5KB	Share
AVR	Response to ASX corporate governance query		26/11/12	320.6KB	Share

AVR Half Yearly Report and Accounts
26/02/14	PRICE SENSITIVE	149.83KB	Share
AVR Admedus's CardioCel Cleared for Sale in the US
10/02/14	PRICE SENSITIVE	279.96KB	Share
AVR Admedus Herpes Interim Phase I Results
03/02/14	PRICE SENSITIVE	277.59KB	Share
AVR Appendix 4C - quarterly
31/01/14	PRICE SENSITIVE	412.6KB	Share
AVR Change in substantial holding
13/01/14		562.85KB	Share
AVR Admedus completes acquisition of manufacturing facility
03/01/14		180.84KB	Share
AVR Admedus End of Year Update
24/12/13	PRICE SENSITIVE	278.97KB	Share
AVR Change of Director's Interest Notice - Correction
18/12/13		316.82KB	Share
AVR Change of Director's Interest Notices
17/12/13		332.46KB	Share
AVR Appendix 3B & Notice under Section 708A
17/12/13		702.92KB	Share
AVR Admedus Acquires Manufacturing Facility
12/12/13	PRICE SENSITIVE	223.93KB	Share
AVR Change of Company Name
21/11/13		189.26KB	Share
AVR Results of Meeting
20/11/13		106.5KB	Share
AVR Presentation to Shareholders
20/11/13		4.72MB	Share
AVR Chairman's Address to Shareholders
20/11/13		111.53KB	Share
AVR Allied makes first sale of CardioCel into Europe
08/11/13	PRICE SENSITIVE	184.28KB	Share
AVR Appendix 3B - Options & Notice under Section 708A
04/11/13		805.7KB	Share
AVR Change in substantial holding
04/11/13		567.9KB	Share
AVR Appendix 4C - quarterly
31/10/13	PRICE SENSITIVE	467.99KB	Share
AVR Allied awarded Industry's Emerging Company of the Year
31/10/13		287.98KB	Share
AVR Response to ASX price query
25/10/13	PRICE SENSITIVE	326.34KB	Share
AVR Change in substantial holding
25/10/13		766.15KB	Share
AVR Top 20 securityholders
25/10/13		258.37KB	Share
AVR Change of Director's Interest Notices
25/10/13		327.81KB	Share
AVR Appendix 3B - Rights Issue
25/10/13		721.4KB	Share
AVR Allied completes oversubscribed $10.4 million Rights Issue
23/10/13		202.78KB	Share
AVR Waiver to Listing Rule 10.13.5
22/10/13		269.14KB	Share
AVR Full Annual Report to shareholders
21/10/13		4.96MB	Share
AVR Proxy Form
21/10/13		332.75KB	Share
AVR Notice of Annual General Meeting
21/10/13		702.98KB	Share
AVR Allied Herpes Phase I Trial progress update
17/10/13	PRICE SENSITIVE	269.31KB	Share
AVR Appendix 3B - Exercise of Options
08/10/13		719.61KB	Share
AVR 8 Surgeons get approval to use CardioCel in adult patients
08/10/13	PRICE SENSITIVE	199.58KB	Share
AVR Dispatch of Offer Document
03/10/13		197.56KB	Share
AVR Change of Director's Interest Notice
27/09/13		224.68KB	Share
AVR Appendix 3B - Exercise of Options
27/09/13		719.27KB	Share
AVR 5 year extension data for Allied's CardioCel
25/09/13	PRICE SENSITIVE	288.61KB	Share
AVR Letter to Ineligible Shareholders
23/09/13		115.54KB	Share
AVR Letter to Eligible Shareholders
23/09/13		117.67KB	Share
AVR Letter to Optionholders
23/09/13		123.74KB	Share
AVR Appendix 3B - Rights Issue
23/09/13		569.04KB	Share
AVR Non-Renounceable Issue Offer Document
23/09/13	PRICE SENSITIVE	501.27KB	Share
AVR Allied announces fully underwritten Rights Issue
23/09/13	PRICE SENSITIVE	312.62KB	Share
AVR Notice under Section 708AA
23/09/13		191.41KB	Share
AVR Exercise of Options
18/09/13		719.18KB	Share
AVR Appendix 3B - Exercise of Options
11/09/13		733.43KB	Share
AVR Investor Presentation
11/09/13		1.2MB	Share
AVR Appendix 3B - Exercise of Options
06/09/13		719.27KB	Share
AVR Appendix 3B - Exercise of Options
04/09/13		718.91KB	Share
AVR Allied Herpes Vaccine Phase I Trial Update
03/09/13	PRICE SENSITIVE	194.72KB	Share
AVR Annual Report to shareholders and Appendix 4E
30/08/13	PRICE SENSITIVE	1.94MB	Share
AVR Appendix 3B - Exercise of Options
30/08/13		630.19KB	Share
AVR Cancellation of Unlisted Options
27/08/13		174.63KB	Share
AVR Appendix 3B - Exercise of Options
27/08/13		719.44KB	Share
AVR Allied granted CE Mark for CardioCel
26/08/13	PRICE SENSITIVE	201.44KB	Share
AVR Response to ASX price query
20/08/13	PRICE SENSITIVE	332.66KB	Share
AVR Change in substantial holding
30/07/13		88.44KB	Share
AVR Appendix 4C - quarterly
30/07/13	PRICE SENSITIVE	469.16KB	Share
AVR Shareholder Newsletter - June 2013
11/07/13		147.59KB	Share
AVR Replacement - Appendix 3B
08/07/13		730.26KB	Share
AVR Section 708A Notice
08/07/13		135.26KB	Share
AVR Appendix 3B
08/07/13		730.55KB	Share
AVR Adult Surgeon approved to use Allied's CardioCel
08/07/13		198.42KB	Share
AVR Allied increases stake in Ian Frazer's Coridon vaccines
01/07/13	PRICE SENSITIVE	196.14KB	Share
AVR Appendix 3B - ESOP
20/06/13		730.25KB	Share
AVR Ceasing to be a substantial holder
20/06/13		459.25KB	Share
AVR Allied's Herpes Vaccine Progresses to Phase 1 Clinical Trial
19/06/13	PRICE SENSITIVE	181.05KB	Share
AVR Change in substantial holding
05/06/13		852.22KB	Share
AVR Allied's CardioCel receives $1.9M grant
03/06/13	PRICE SENSITIVE	225.42KB	Share
AVR Allied's CardioCel in Spotlight at International Conferences
06/05/13	PRICE SENSITIVE	202.44KB	Share
AVR Appendix 3B - Options
02/05/13		729.96KB	Share
AVR Appendix 4C - quarterly
29/04/13	PRICE SENSITIVE	470.69KB	Share
AVR Allied Announces Additional Early Access for CardioCel
08/04/13	PRICE SENSITIVE	278.62KB	Share
AVR Shareholder Newsletter - March 2013
27/03/13		860.1KB	Share
AVR Clinical Trial Extension Study Update - No Calcification
06/03/13	PRICE SENSITIVE	202.33KB	Share
AVR Half Yearly Report
22/02/13	PRICE SENSITIVE	134.2KB	Share
AVR Response to ASX query
19/02/13	PRICE SENSITIVE	352.13KB	Share
AVR Replacement form - Change in substantial holding
15/02/13		128.15KB	Share
AVR Allied announces ISO 13485 certification for CardioCel
13/02/13	PRICE SENSITIVE	202.01KB	Share
AVR +AVXCeasing to be a substantial holder
11/02/13		140.96KB	Share
AVR Amended form - change in substantial holding
07/02/13		846.12KB	Share
AVR Allied's CardioCel superior for seeding stem cells
06/02/13	PRICE SENSITIVE	704.27KB	Share
AVR Change in substantial holding
04/02/13		1.25MB	Share
AVR Appendix 4C - quarterly
30/01/13	PRICE SENSITIVE	449.71KB	Share
AVR Change of Director's Interest Notices
29/01/13		309.94KB	Share
AVR Top 20 securityholders
29/01/13		229.74KB	Share
AVR Appendix 3B - Share Purchase Plan
29/01/13		752.77KB	Share
AVR Allied closes SPP, bringing total capital raised to $4.6M
23/01/13		266.56KB	Share
AVR Allied's hernia and pelvic floor results
10/01/13	PRICE SENSITIVE	280.04KB	Share
AVR Top 20 securityholders
21/12/12		228.99KB	Share
AVR Appendix 3B and Section 708A(5)(e) Notice
21/12/12		752.61KB	Share
AVR Allied announces successful grant for Coridon's HPV vaccine
20/12/12	PRICE SENSITIVE	266.22KB	Share
AVR Allied Announces Placement and Share Purchase Plan
17/12/12	PRICE SENSITIVE	207.44KB	Share
AVR Trading Halt
13/12/12	PRICE SENSITIVE	75.83KB	Share
AVR Re-issue correction to Appendix 3B
10/12/12		562.45KB	Share
AVR Change of Director's Interest Notice
07/12/12		291.5KB	Share
AVR Appendix 3B
07/12/12		402.47KB	Share
AVR Change in substantial holding
07/12/12		84.09KB	Share
AVR Allied's CardioCel shows regeneration in heart valve study
28/11/12	PRICE SENSITIVE	221.5KB	Share
AVR Response to ASX corporate governance query
26/11/12		320.6KB	Share

REFRESH

First 8 9 10 11 12

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $6.05		Change 0.450(8.04%)		Mkt cap ! $92.87M

Open	High	Low	Value	Volume
$5.98	$6.07	$5.83	$260.3K	43.32K

Buyers (Bids)

No.	Vol.	Price($)
2	4518	$6.02

Sellers (Offers)

Price($)	Vol.	No.
$6.39	2142	3

View Market Depth

No.	Vol.	Price($)
2	4518	6.020
1	124	6.000
2	663	5.960
1	2000	5.710
2	1046	5.300

Price($)	Vol.	No.
6.390	2142	3
6.400	449	1
6.500	1230	3
6.600	3823	2
6.740	48000	1

Last trade - 12.57pm 25/08/2025 (20 minute delay)


Last $5.96		Change 0.450 ( 6.43 %)
Open	High	Low	Volume
$5.95	$5.96	$5.95	1680
Last updated 11.55am 25/08/2025 ?

AVR (ASX) Chart

ANTERIS TECHNOLOGIES GLOBAL CORP. - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available